Blood vessel assembly from multipotent hemangioma-derived stem cells
来自多能血管瘤干细胞的血管组装
基本信息
- 批准号:8248244
- 负责人:
- 金额:$ 43.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-04-01 至 2014-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgeAge-YearsAngiogenesis InhibitorsAnimal ModelBasic ScienceBehaviorBenignBirthBlood VesselsCell ProliferationCellsChildCommon NeoplasmDataDevelopmentDifferentiation and GrowthDrug Delivery SystemsEndothelial CellsEuropeanExhibitsFDA approvedFamilyGoalsGrowthHealthHemangiomaHumanImmuneImmunodeficient MouseIn VitroInfantKnowledgeLeadLesionLifeLife Cycle StagesMeasuresMesenchymal Stem CellsModelingMolecularMusNeoplasms in Vascular TissueNewborn InfantNormal CellNormal tissue morphologyPaperPathway interactionsPediatric NeoplasmPericytesPharmaceutical PreparationsPhaseProcessProliferatingPropertyResearchRoleSignal TransductionSmooth Muscle MyocytesSpecimenStem cellsStrawberry nevusTestingTranslatingTumor AngiogenesisVascular Endothelial Growth Factor BVascular Endothelial Growth Factorsbasecell growthcell typeclinical applicationearly childhoodin vivoinfancyinsightnovelpreventself-renewalsmall hairpin RNAstem cell differentiationtissue regenerationtissue repairtranscription factortumor
项目摘要
DESCRIPTION (provided by applicant): Infantile hemangioma is a common childhood tumor composed of disorganized blood vessels and immature endothelial cells. Hemangioma follows a unique life-cycle in which the tumor appears soon after birth and grows dramatically during infancy. This "proliferating phase" is followed by a spontaneous but slow "involuting phase" that begins after age one. By five to eight years of age, most hemangiomas have reached the "involuted phase" at which point the tumor mass has been replaced by a fibrofatty residuum. Hence, infantile hemangioma is a human vascular anomaly from which we might gain important insight into how blood vessels are formed and how they regress. Our goal has been to find the cell that initiates growth and expansion of IH and to establish an animal model that closely reflects this human vascular tumor. Indeed, we have now isolated a multi-potent hemangioma stem cell (HemSC) from 30 different proliferating hemangioma specimens removed from infants with endangering hemangiomas, and demonstrated their robust self-renewal capacity, multi- lineage differentiation potential and ability to form hemangioma-like blood vessels in vivo in immunodeficient mice (Khan, Boscolo et al, J Clin Invest. 2008). In summary, this paper identifies the HemSC as the cellular origin of infantile hemangioma and provides the first animal model that truly reflects this vascular lesion. We had previously isolated and studied hemangioma-derived endothelial cells (HemECs) and hemangioma-derived endothelial progenitor cells (HemEPCs) but these cells do not form blood vessels when injected into immune-deficient mice, suggesting that the cells may be too differentiated to recapitulate infantile hemangioma. Our current goal is to further our studies on HemSC and HemEPCs/HemECs and how these cells interact to cause the aberrant vessel formation that occurs in infantile hemangioma. We will purse three specific aims. The first will focus on HemSC differentiation into pericytes and the potential influence of EPCs on hemangioma vessel development. The second aim will focus on VEGF-R1 in HemSC differentiation into endothelial cells. The third aim will be to screen FDA-approved drugs with anti-angiogenic activity for ability to inhibit HemSC growth in vitro and blood vessel formation in vivo using the models we have developed. These three aims represent cellular (Aim 1), molecular (Aim 2) and translational (Aim 3) approaches to advance our understanding of hemangioma and to identify potential drugs that will stop the growth and blood vessel formation that occurs in hemangima. Furthermore, this research may have relevance to other vascular anomalies, vascular tumors and tumor angiogenesis. Finally, because this research focuses on mechanisms leading to blood vessel formation, it may reveal insights into how human vascular progenitor cells can be used to rebuild vascular networks for tissue regeneration. PUBLIC HEALTH RELEVANCE: This proposal will study stem cells isolated from a common childhood tumor known as infantile hemangioma. We hope to understand how and why these stem cells have become disrupted, such that instead of following a normal healthy pathway to become normal cells and tissue, the hemangioma-derived stem cells form a mass of disorganized blood vessels that grows dramatically during infancy. The results from this study may lead to new, fast-acting and safe treatments for children with endangering hemangiomas. In addition, the studies may provide fundamental insights into the behavior of human vascular progenitor cells which could then be applied to strategies to use such progenitor cells for tissue repair and regeneration, and specifically to build healthy vascular networks.
描述(申请人提供):婴儿血管瘤是一种常见的儿童肿瘤,由紊乱的血管和未成熟的内皮细胞组成。血管瘤有一个独特的生命周期,肿瘤在出生后不久就会出现,并在婴儿期急剧增长。这个“增殖期”之后是一个自发但缓慢的“退化期”,从一岁以后开始。到五到八岁时,大多数血管瘤已经到了“消退期”,此时肿块已经被纤维脂肪残留物所取代。因此,婴儿血管瘤是一种人类血管异常,我们可以从中获得关于血管是如何形成和如何退化的重要见解。我们的目标一直是找到启动IH生长和扩张的细胞,并建立一个接近反映这种人类血管肿瘤的动物模型。事实上,我们现在已经从30个不同的增殖性血管瘤标本中分离出了一种多潜能的血管瘤干细胞(HemSC),这些标本取自患有危险血管瘤的婴儿,并展示了它们强大的自我更新能力、多系分化潜力以及在免疫缺陷小鼠体内形成血管瘤样血管的能力(Khan,Boscolo等,J Clin Invest)。2008年)。综上所述,本论文认为血管干细胞是婴幼儿血管瘤的细胞起源,并提供了第一个真实反映这一血管病变的动物模型。我们之前已经分离和研究了血管瘤来源的内皮细胞(HemECs)和血管瘤来源的内皮祖细胞(HemEPC),但这些细胞在注射到免疫缺陷小鼠体内时不能形成血管,这表明这些细胞可能分化过高,无法重现婴儿血管瘤。我们目前的目标是进一步研究血液干细胞和血液内皮祖细胞/血管内皮细胞,以及这些细胞如何相互作用导致婴儿血管瘤中出现的异常血管形成。我们将追求三个具体目标。第一部分将着重于向周细胞分化的研究以及内皮祖细胞对血管瘤血管发育的潜在影响。第二个目标将集中在血管内皮生长因子-R1在血管内皮细胞分化中的作用。第三个目标是利用我们开发的模型筛选FDA批准的具有抗血管生成活性的药物,以了解其在体外抑制血液干细胞生长和体内血管形成的能力。这三个目标分别代表细胞(目标1)、分子(目标2)和翻译(目标3)方法,以促进我们对血管瘤的理解,并确定将阻止血管生长和血管形成的潜在药物。此外,本研究还可能与其他血管畸形、血管肿瘤和肿瘤血管生成相关。最后,由于这项研究集中在导致血管形成的机制上,它可能会揭示如何利用人类血管前体细胞来重建血管网络,以实现组织再生。与公共卫生相关:这项提案将研究从一种常见的儿童肿瘤--婴儿血管瘤中分离出的干细胞。我们希望了解这些干细胞是如何以及为什么被破坏的,以至于血管瘤来源的干细胞不是沿着正常的健康途径变成正常的细胞和组织,而是形成了一大堆在婴儿期急剧增长的无序血管。这项研究的结果可能会为患有危险血管瘤的儿童带来新的、快速有效和安全的治疗方法。此外,这些研究可能会为人类血管前体细胞的行为提供基本的见解,然后可以应用于利用这些前体细胞进行组织修复和再生的策略,特别是建立健康的血管网络。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Joyce E. Bischoff其他文献
Joyce E. Bischoff的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Joyce E. Bischoff', 18)}}的其他基金
Pediatric Surgeon-Scientist Training Program in Vascular Diseases
小儿外科医生-科学家血管疾病培训计划
- 批准号:
10331916 - 财政年份:2022
- 资助金额:
$ 43.07万 - 项目类别:
Pediatric Surgeon-Scientist Training Program in Vascular Diseases
小儿外科医生-科学家血管疾病培训计划
- 批准号:
10619547 - 财政年份:2022
- 资助金额:
$ 43.07万 - 项目类别:
Capillary malformation: From somatic GNAQ mutations to disrupted endothelial biology
毛细血管畸形:从体细胞 GNAQ 突变到内皮生物学破坏
- 批准号:
10206231 - 财政年份:2016
- 资助金额:
$ 43.07万 - 项目类别:
Capillary malformation: From somatic GNAQ mutations to disrupted endothelial biology
毛细血管畸形:从体细胞 GNAQ 突变到内皮生物学破坏
- 批准号:
10630310 - 财政年份:2016
- 资助金额:
$ 43.07万 - 项目类别:
Capillary malformation: From somatic GNAQ mutations to disrupted endothelial biology
毛细血管畸形:从体细胞 GNAQ 突变到内皮生物学破坏
- 批准号:
10058384 - 财政年份:2016
- 资助金额:
$ 43.07万 - 项目类别:
Capillary malformation: From somatic GNAQ mutations to disrupted endothelial biology
毛细血管畸形:从体细胞 GNAQ 突变到内皮生物学破坏
- 批准号:
10414083 - 财政年份:2016
- 资助金额:
$ 43.07万 - 项目类别:
Capillary malformation: From somatic GNAQ mutations and disrupted endothelial biology
毛细血管畸形:来自体细胞 GNAQ 突变和内皮生物学破坏
- 批准号:
9244833 - 财政年份:2016
- 资助金额:
$ 43.07万 - 项目类别:
Blood vessel assembly from multipotent hemangioma-derived stem cells
来自多能血管瘤干细胞的血管组装
- 批准号:
10609870 - 财政年份:2009
- 资助金额:
$ 43.07万 - 项目类别:
Blood vessel assembly from multipotent hemangioma-derived stem cells
来自多能血管瘤干细胞的血管组装
- 批准号:
9973341 - 财政年份:2009
- 资助金额:
$ 43.07万 - 项目类别:
Blood vessel assembly from multipotent hemangioma-derived stem cells
来自多能血管瘤干细胞的血管组装
- 批准号:
7789467 - 财政年份:2009
- 资助金额:
$ 43.07万 - 项目类别:
相似国自然基金
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
- 批准号:JCZRQN202500010
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
- 批准号:2025JJ70209
- 批准年份:2025
- 资助金额:0.0 万元
- 项目类别:省市级项目
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
- 批准号:
- 批准年份:2024
- 资助金额:0 万元
- 项目类别:面上项目
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
- 批准号:2023JJ50274
- 批准年份:2023
- 资助金额:0.0 万元
- 项目类别:省市级项目
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
- 批准号:
- 批准年份:2022
- 资助金额:33 万元
- 项目类别:地区科学基金项目
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
- 批准号:n/a
- 批准年份:2022
- 资助金额:10.0 万元
- 项目类别:省市级项目
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
- 批准号:81973577
- 批准年份:2019
- 资助金额:55.0 万元
- 项目类别:面上项目
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
- 批准号:81602908
- 批准年份:2016
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
高血糖激活滑膜AGE-RAGE-PKC轴致骨关节炎易感的机制研究
- 批准号:81501928
- 批准年份:2015
- 资助金额:18.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341426 - 财政年份:2024
- 资助金额:
$ 43.07万 - 项目类别:
Continuing Grant
Collaborative Research: Resolving the LGM ventilation age conundrum: New radiocarbon records from high sedimentation rate sites in the deep western Pacific
合作研究:解决LGM通风年龄难题:西太平洋深部高沉降率地点的新放射性碳记录
- 批准号:
2341424 - 财政年份:2024
- 资助金额:
$ 43.07万 - 项目类别:
Continuing Grant
PROTEMO: Emotional Dynamics Of Protective Policies In An Age Of Insecurity
PROTEMO:不安全时代保护政策的情绪动态
- 批准号:
10108433 - 财政年份:2024
- 资助金额:
$ 43.07万 - 项目类别:
EU-Funded
The role of dietary and blood proteins in the prevention and development of major age-related diseases
膳食和血液蛋白在预防和发展主要与年龄相关的疾病中的作用
- 批准号:
MR/X032809/1 - 财政年份:2024
- 资助金额:
$ 43.07万 - 项目类别:
Fellowship
Atomic Anxiety in the New Nuclear Age: How Can Arms Control and Disarmament Reduce the Risk of Nuclear War?
新核时代的原子焦虑:军控与裁军如何降低核战争风险?
- 批准号:
MR/X034690/1 - 财政年份:2024
- 资助金额:
$ 43.07万 - 项目类别:
Fellowship
Walkability and health-related quality of life in Age-Friendly Cities (AFCs) across Japan and the Asia-Pacific
日本和亚太地区老年友好城市 (AFC) 的步行适宜性和与健康相关的生活质量
- 批准号:
24K13490 - 财政年份:2024
- 资助金额:
$ 43.07万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Discovering the (R)Evolution of EurAsian Steppe Metallurgy: Social and environmental impact of the Bronze Age steppes metal-driven economy
发现欧亚草原冶金的(R)演变:青铜时代草原金属驱动型经济的社会和环境影响
- 批准号:
EP/Z00022X/1 - 财政年份:2024
- 资助金额:
$ 43.07万 - 项目类别:
Research Grant
ICF: Neutrophils and cellular senescence: A vicious circle promoting age-related disease.
ICF:中性粒细胞和细胞衰老:促进与年龄相关疾病的恶性循环。
- 批准号:
MR/Y003365/1 - 财政年份:2024
- 资助金额:
$ 43.07万 - 项目类别:
Research Grant
Doctoral Dissertation Research: Effects of age of acquisition in emerging sign languages
博士论文研究:新兴手语习得年龄的影响
- 批准号:
2335955 - 财政年份:2024
- 资助金额:
$ 43.07万 - 项目类别:
Standard Grant
Shaping Competition in the Digital Age (SCiDA) - Principles, tools and institutions of digital regulation in the UK, Germany and the EU
塑造数字时代的竞争 (SCiDA) - 英国、德国和欧盟的数字监管原则、工具和机构
- 批准号:
AH/Y007549/1 - 财政年份:2024
- 资助金额:
$ 43.07万 - 项目类别:
Research Grant